Biohaven (BHVN) Free Cash Flow (2021 - 2026)
Biohaven (BHVN) posted Free Cash Flow of -$149.9 million for Q1 2026, down 14.73% sequentially from -$130.7 million in Q4 2025, and up 9.46% YoY from -$137.0 million in Q1 2025.
Biohaven (BHVN) Free Cash Flow (2021 - 2026) Analysis & Trends
Biohaven has reported Free Cash Flow for 6 years, with the latest figure at -$149.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 9.46% year-over-year to -$149.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$594.5 million (up 8.4% YoY) and the FY2025 annual result came in at -$610.2 million, down 4.03% from the prior year.
- Free Cash Flow slipped to -$149.9 million in Q1 2026 per BHVN's latest filing, from -$130.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$45.0 million in Q2 2023 and troughed at -$170.8 million in Q4 2024.
- A 5-year average of -$116.8 million and a median of -$115.4 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 34.7% in 2023, then tumbled 279.54% in 2024.
- Over 5 years, Free Cash Flow stood at -$75.7 million in 2022, then slumped by 52.37% to -$115.4 million in 2023, then sank by 48.06% to -$170.8 million in 2024, then grew by 23.49% to -$130.7 million in 2025, then declined by 14.73% to -$149.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$149.9 million, -$130.7 million, and -$145.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | -85.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.55 Mn |
| Jun 30, 2026 | -85.55 Mn |
| Mar 31, 2026 | -149.92 Mn |
| Mar 31, 2026 | -149.92 Mn |
| Dec 31, 2025 | -130.67 Mn |
| Dec 31, 2025 | -130.67 Mn |
| Sep 30, 2025 | -145.73 Mn |
| Sep 30, 2025 | -145.73 Mn |
| Jun 30, 2025 | -168.17 Mn |
| Jun 30, 2025 | -168.17 Mn |
| Mar 31, 2025 | -165.59 Mn |
| Mar 31, 2025 | -165.59 Mn |
| Dec 31, 2024 | -170.79 Mn |
| Dec 31, 2024 | -170.79 Mn |
| Sep 30, 2024 | -141.89 Mn |
| Sep 30, 2024 | -141.89 Mn |
| Jun 30, 2024 | -170.75 Mn |
| Jun 30, 2024 | -170.75 Mn |
| Mar 31, 2024 | -103.08 Mn |
| Mar 31, 2024 | -103.08 Mn |